Abstracts Archive - Page 1995 of 2425 - ACR Meeting Abstracts

Abstract Number: 844 • 2014 ACR/ARHP Annual Meeting
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
Kenneth G. Saag¹, Kevin L. Winthrop², Daniel E. Furst³, Kimberly Alexander⁴, Angelika Jahreis⁵, Carol Chung⁶ and Kurt Oelke⁷, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³University of California at Los Angeles, Los Angeles, CA, ⁴Epidemiology, Genentech, Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Genentech, Inc, South San Francisco, CA, ⁷Rheumatic Disease Center, Glendale, WI
Background/Purpose: Rituximab (RTX) is an approved treatment for rheumatoid arthritis (RA) in patients (pts) with an inadequate response to anti–TNF therapy (aTNF-IR). Long-term infection risk…
Abstract Number: 843 • 2014 ACR/ARHP Annual Meeting
Exercise Is Associated with Protective Cardiovascular Risk Profile Including Increased HDL Particle Number in Patients with Rheumatoid Arthritis
Kevin Byram¹, Annette Oeser², MacRae F. Linton², Sergio Fazio², C Michael Stein² and Michelle Ormseth³, ¹Internal Medicine, Vanderbilt University, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased cardiovascular risk. In the general population, exercise improves several cardiovascular risk factors, including HDL cholesterol concentrations. Although…
Abstract Number: 842 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jie Zhang¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Huifeng Yun⁵, Paul M. Muntner⁶, Emily Levitan⁶, Monica Safford⁷, Kenneth G. Saag⁸, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁷, ¹Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recently cholesterol treatment guidelines recommend that diabetes (DM) should be considered a CVD risk equivalent to a history of coronary heart disease (CHD). Despite…
Abstract Number: 841 • 2014 ACR/ARHP Annual Meeting
Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients
J An¹, E Alemao², K Reynolds³, H Kawabata², D H Solomon⁴, K P Liao⁴ and T C Cheetham³, ¹Western University of Health Sciences, Pomona, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Kaiser Permanente Southern California, Pasadena, CA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Lipid levels are known to be lower in patients with RA compared with the general population; however, differences in cardiovascular (CV) risk associated with…
Abstract Number: 840 • 2014 ACR/ARHP Annual Meeting
Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen-Specific Anti-Citrullinated Protein Antibodies, and Mortality in Rheumatoid Arthritis
E. Blair Solow¹, Fang Yu², Geoffrey M. Thiele³, Jeremy Sokolove^4,5, William H. Robinson^6,7, Zachary M. Pruhs³, Kaleb Michaud^8,9, Alan R. Erickson⁹, Harlan Sayles⁹, Gail S. Kerr¹⁰, Angelo L. Gaffo¹¹, Liron Caplan¹², Lisa A. Davis¹³, Grant W. Cannon¹⁴, Andreas M. Reimold¹⁵, Joshua Baker¹⁶, Pascale Schwab^17,18, Daniel Anderson⁹ and Ted R. Mikuls⁹, ¹Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁵Stanford University School of Medicine, Stanford, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸National Data Bank for Rheumatic Diseases, Wichita, KS, ⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁰Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹¹Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, ¹²Div of Rheumatology, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ¹³Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ¹⁴Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ¹⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁶Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁷Department of Internal Medicine, Division of Rheumatology, Portland VA Medical Center, Portland, OR, ¹⁸Internal Medicine, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality due to cardiovascular disease (CVD). Select antigen-specific anti-citrullinated protein antibodies (ACPA) are associated with atherosclerotic…
Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses
Tomohisa Okamura¹, Kaoru Morita¹, Mariko Inoue¹, Toshihiko Komai¹, Yukiko Iwasaki¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Hirofumi Shoda², Keishi Fujio² and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…
Abstract Number: 858 • 2014 ACR/ARHP Annual Meeting
ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets
Li Chun Wang¹, Stuart Perper¹, Annette Schwartz², Christian Goess³, Liz O'connor⁴, Dawna Hartman², Candace Graff², Andrew Souers⁵, Joel Leverson⁵, Steven Elmore⁵ and Lisa Olson², ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, North Chicago, IL
Background/Purpose Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. Navitoclax, a selective inhibitor of both BCL-2 and BCL-X(L) demonstrated…
Abstract Number: 856 • 2014 ACR/ARHP Annual Meeting
A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus
Silvio M. Vieira¹, Andrew Yu¹, Michael Hiltesperger¹, Odelya E. Pagovich¹, Eleni Tiniakou¹, William Ruff², John Sterpka¹ and Martin Kriegel^2,3, ¹Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, New Haven, CT, ³Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The etiology of lupus-associated antiphospholipid syndrome (APS) is unknown but microbial triggers have been implicated in transient antiphospholipid antibody production in both mice and…
Abstract Number: 854 • 2014 ACR/ARHP Annual Meeting
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial
Chi Chiu Mok¹, Angela Li², Kar Li Chan¹ and Ling Yin Ho¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Radiology, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To compare the efficacy of golimumab(GLM) and pamidronate(PAM) in the treatment of SpA.Methods Inclusion criteria: (1) patients ≥18 years of age; (2) fulfills the…
Abstract Number: 855 • 2014 ACR/ARHP Annual Meeting
Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Etanercept
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Previous studies evaluating predictors of major clinical response in patients with non-radiographic axial SpA (nr-axSpA) receiving treatment with anti-TNF agents have been limited by…
Abstract Number: 853 • 2014 ACR/ARHP Annual Meeting
Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study from the ARTIS and Danbio Registers
Johan Askling¹, Lene Dreyer², Merete Lund Hetland³, Lennart Jacobsson⁴, Lars-Erik Kristensen⁵, Bente Glintborg⁶, . ARTIS and DANBIO study groups⁷ and Karin Hellgren⁸, ¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²Gentofte University Hospital, Hellreup, Denmark, ³Glostrup University Hospital, Glostrup, Denmark, ⁴Sahlgrenska Academy, Gothenburg, Sweden, ⁵Lund University, Lund, Sweden, ⁶Gentofte University Hospital, Gentofte, Denmark, ⁷Karolinska Institutet, stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden
Background/Purpose Most studies of the safety profile of TNF inhibitors (TNFi) - in particular in relation to cancer risks - have been performed in patients…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 857 • 2014 ACR/ARHP Annual Meeting
Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors
Chaim O. Jacob, Ning Yu and William Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: BAFF, a potent B cell survival factor, is an established therapeutic target in SLE, with the anti-BAFF antibody, belimumab, being FDA-approved for the treatment…
Abstract Number: 831 • 2014 ACR/ARHP Annual Meeting
Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)
Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa Blagojevic-Bucknall and Christian Mallen, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Acute pseudogout is the most dramatic clinical manifestation of calcium pyrophosphate crystal deposition (CPPD). CPPD is most commonly sporadic and age-related but can rarely…
Abstract Number: 830 • 2014 ACR/ARHP Annual Meeting
Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Raymond P. Warrell Jr.¹, Anna Klukovits², Keith Barnes³, Chitkala Satyanarayana⁴, Chris Cheeseman⁵ and John Piwinski¹, ¹Relburn-Metabolomics, Inc., Westfield, NJ, ²SOLVO Biotechnology, Budapest, Hungary, ³AMRI, Albany, NY, ⁴AMRI, Singapore, Singapore, ⁵University of Alberta, Alberta, AB, Canada
Background/Purpose: A prototype anticancer drug (RLBN1001) induced marked hypouricemia in studies of > 350 human subjects. Preliminary exploration suggested dual effects on uric acid (UA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].